Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Gastroesophageal reflux disease (GERD) is common in infants and children and has been estimated to affect as much as 3.3% of the pediatric population.1 Despite this, we still struggle with the management of GERD. With a growing body of literature that illustrates a lack of efficacy and alarming adverse effects, there is increasing reason to limit the empirical use of acid suppression therapy in children.
Menchise AN, Cohen MB. Acid-Reducing Agents in Infants and ChildrenFriend or Foe?. JAMA Pediatr. 2014;168(10):888-890. doi:10.1001/jamapediatrics.2014.1263